Endocrine Abstracts

There are two issues: i) dopamine agonist (DA) safety for mother and baby, and ii) risk of oestrogen-induced prolactinoma enlargement. Bromocriptine (BC) and Cabergoline (CAB) are both safe for ovulation induction but the safety database is larger for BC (6239 pregnancies) than for CAB (789). Neither drug causes increases in miscarriage, premature delivery, multiple births or congenital malformations, compared to data for normal pregnancy. Risk of symptomatic tumour enlargemen...

In 2011 is the 40th anniversary of prolactin (PRL) characterisation as a distinct hormone. Only 30 years ago most patients with large pituitary tumours received primary surgery (often transcranial) followed by routine radiotherapy – treatments associated with significant morbidity and hypopituitarism. Much therapeutic progress has been made; effective medical treatments now exist for many pituitary tumour subtypes, particularly the use of long-acting dopamine agonists (DA...

John S Bevan, Department of Endocrinology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK. AbstractJohn S Bevan is senior Consultant Endocrinologist at Aberdeen Royal Infirmary and Honorary Professor of Endocrinology at Aberdeen University. He qualified MB ChB, with Honours, from Edinburgh University in 1978 and his clinical training in Medicine & Endocrinology took place in Edinburgh, Oxford and Ca...

Introduction: A joint ‘late effects’ clinic for follow-up of survivors of childhood cancer has been in operation in our institution since 1995. In patients who have undergone cranial irradiation, dynamic anterior pituitary function testing using a standard insulin tolerance test (ITT) or, if contraindicated, a glucagon or arginine/GHRH test was undertaken at around five yearly intervals.Methods: Case note review was undertaken for 24 patients (...

Purpose: High serum prolactin concentrations have been associated with adverse health outcomes in some but not all studies. This study aimed to examine the morbidity and all-cause mortality associated with hyperprolactinaemia.Methods: A population-based matched cohort study in Tayside (Scotland, UK) from 1988 to 2014. Record-linkage technology (biochemistry, prescribing, hospital admissions, cancer registration, mat...

Purpose: High serum prolactin concentrations have been associated with adverse health outcomes in some but not all studies. This study aimed to examine the morbidity and all-cause mortality associated with hyperprolactinaemia.Methods: A population-based matched cohort study in Tayside (Scotland, UK) from 1988 to 2014. Record-linkage technology (biochemistry, prescribing, hospital admissions, cancer registration, mat...

The epidemiology of hyperprolactinaemia is not well characterised in the literature. Using unique patient identifier we were able to link data from biochemistry, prescribing, hospital admissions, radiology, general registry office and maternity data. Observational data was collected for Tayside Scotland between 1993 and 2013. Any patient with a serum prolactin measurement >1000 mU/l or at least three prescriptions for a dopamine agonist were included. Patients who were pre...

Introduction: PRIMARYS provided evidence for TVR with monthly LAN-ATG 120 mg in treatment-naïve acromegalic patients (63% achieved TVR ≥20% with a favourable safety profile). To help clinicians with therapeutic management of acromegaly, tumour responsive over time needs to be further explored.Methods: PRIMARYS was an international, multicentre, open-label, single-arm study of 90 treatment-naïve acromegalic patients with pituitary macroade...

Introduction: The PRIMARYS study demonstrated primary treatment with lanreotide Autogel 120 mg could achieve favourable tumour and hormone response rates in a large cohort of acromegalic patients. Here, we further interrogate the PRIMARYS database on the relationship between the tumour volume responsiveness and hormonal control.Methods: PRIMARYS was an international, multicentre, open-label, single-arm study of 90 treatment-naïve acromegalic patient...

Introduction: First-line somatostatin analogue treatment may be an effective alternative option to surgery for some patients with GH-secreting pituitary macroadenoma. The PRIMARYS study aimed to investigate the impact of primary lanreotide Autogel 120 mg treatment on tumour volume and GH/IGF1 control in treatment-naïve acromegalic patients over a one-year time course.Methods: PRIMARYS was an international, multicentre, open-label, single arm, phase ...